Summary
The pharmacokinetics of tosufloxacin enantiomers after oral administration of racemic tosufloxacin were examined in healthy volunteers. Only small differences were observed in time to peak concentration (2.6±0.3 [mean ± SEM] h for (+)-tosufloxacin vs 2.4±0.2 h for (−)-tosufloxacin), elimination half-life (3.61±0.24 h vs 3.49±0.23 h), and area under the curve (2.78±0.19 h·μg/ml vs 2.87±0.19 h·μg/ml); however, peak concentration (0.40±0.03 μg/ml vs 0.44±0.03 μg/ml), renal clearance (226±10 ml/min vs 202±10 ml/min), and urinary recovery (35.4±2.2% vs 32.4±1.9%) differed significantly between enantiomers.
References
Fujimaki K, Noumi T, Hamana Y, Mitsuhashi S, Inoue M (1988) Antibacterial activity of T-3262. Chemotherapy 36 [Suppl 9]: 1–18
Rosen T, Chu DTW, Lico IM, Fernandes PB, Shen L, Borodkin S, Pernet AG (1988) Asymmetric synthesis and properties of the enantiomers of the antibacterial agent 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride. J Med Chem 31: 1586–1590
Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4: 879–885
Yasuda T, Watanabe Y, Hayashi T, Kitayama R (1988) Serum protein binding of T-3262. Chemotherapy 36 [Suppl 9]: 143–148
Tai M, Sugimoto Y, Katayama Y, Maeda T (1988) Phase I study on T-3262 metabolites in serum, urine and feces. Chemotherapy 36 [Suppl 9]: 208–215
Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M (1986) Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother 29: 163–164
Lehr KH, Damm P (1988) Quantification of the enantiomers of ofloxacin in biological fluids by high-performance liquid chromatography. J Chromatogr 425: 153–161
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Minami, R., Inotsume, N., Nakamura, C. et al. Stereoselective analysis of the disposition of tosufloxacin enantiomers in man. Eur J Clin Pharmacol 45, 489–491 (1993). https://doi.org/10.1007/BF00315523
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315523